Biosortia Microbiomics to Present at Biotech Showcase™ 2023

Biosortia’s proven technology obtains nature’s previously inaccessible drug-like small molecules for treatments and cures

January 6, 2023.

DUBLIN, Ohio – January 10, 2023 – Biosortia Microbiomics, the small molecule drug discovery platform and the only company practicing microbiome mining announced that it is presenting at Biotech Showcase™ 2023, taking place on January 9-11 in San Francisco, CA. This year, registered attendees can view Biosortia Microbiomics’ presentation live, and with 24/7 on-demand access, attendees can also view recorded presentations at their convenience when scheduling does not allow viewing during the main event week.

Ross Youngs, CEO, and Founder of Biosortia Microbiomics will be presenting on January 10 at 10:00 am PT at Franciscan A (ballroom level) at the event. In his session, Ross will explore the current problems with drug costs and drug discovery and educate the audience about industrial-scale microbiome mining and how it fits into the solution.

Ross will discuss how in just the past ten years, new drug costs have increased by 300% with minimal progress in finding new cures or treatments. And although small molecules are 90% of drugs on the shelf, the most sought-after drug-like small molecules can’t be obtained by indirect methods. Ross will also share how Biosortia’s technology, which is backed by the U.S. Air Force Research Laboratory, ARPA-E, DARPA and NIH are proven for obtaining nature’s drug-like small molecules, which were previously inaccessible, for treatments and cures.

“The capabilities and potential impact of Biosortia’s technology on the drug discovery industry is what motivates me and my team,” says Youngs. “We’ve received incredible support through funding from major organizations that allowed us to prove the effectiveness of our technology. The next step for us is to continue raising funds in order to put the technology to work and collaborate with researchers and academia to accelerate discovery in critical life science areas.”

Biotech Showcase™, produced by Demy-Colton and EBD Group, is an investor conference focused on driving advances in therapeutic development by providing a sophisticated networking platform for executives and investors that fosters investment and partnership opportunities. The conference takes place each year during the course of one of the industry’s largest gatherings and busiest weeks.

“We are delighted that Biosortia Microbiomics will be joining us in San Francisco and presenting at Biotech Showcase™ this year,” said Sara Demy, CEO of Demy-Colton. “Biotech Showcase™ is a prime occasion for life science entrepreneurs and investors to come together to discover the potential of innovative technologies that will drive the future of drug discovery.”

ABOUT BIOTECH SHOWCASE™

Biotech Showcase™ is an investor and networking conference devoted to providing private and public biotechnology and life sciences companies with an opportunity to present to, and meet with, investors and pharmaceutical executives in one place. Investors and biopharmaceutical executives from around the world gather at Biotech Showcase™ during this bellwether week which sets the tone for the coming year. Now in its 15th year, this well-established, highly respected conference features multiple tracks of presenting companies, plenary sessions, workshops, networking, and an opportunity to schedule one-to-one meetings. Biotech Showcase™ is produced by Demy-Colton and EBD Group. Both organizations have a long history of producing high-quality programs that support biotechnology and the broader life sciences industry.

ABOUT BIOSORTIA MICROBIOMICS

Founded in 2012, Biosortia Microbiomics invented the practice of Microbiome Mining, using its technology and equipment to obtain, process, analyze, and prepare previously inaccessible microbial small molecules and datasets for therapeutic drug discovery. With over $9 million in funding from the U.S. Air Force Research Laboratory, ARPA-E, DARPA, and NIH, Biosortia is the only company practicing microbiome mining and its technologies will accelerate discovery in critical life science areas including new opportunities with next-generation drugs, agrochemicals, longevity, sustainability, advanced energy, and more.

CONTACT

North 6th Agency for Univenture
un********@n6*.com
(212)334-9753